Weiqin Yang

Weiqin Yang

Auto-generated profile, based on publicly available information

Weiqin Yang

School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
WYWeiqin Yang
Weiqin Yang
YFYu Feng
Yu Feng
JZJingying Zhou
Jingying Zhou
OCOtto Ka-Wing Cheung
Otto Ka-Wing Cheung
JCJianquan Cao
Jianquan Cao
ACAlfred Cheng
Alfred Cheng
Insufficient T cell infiltration into noninflamed tumors, such as hepatocellular carcinoma (HCC), restricts the effectiveness of immune-checkpoint blockade (ICB) for a subset of patients. Epigenetic therapy provides further opportunities to rewire cancer-associated transcriptional programs, but whether and how selective epigenetic inhibition counteracts the immune-excluded phenotype remain incompletely defined. Here, we showed that pharmacological inhibition of histone deacetylase 8 (HDAC8), a histone H3 lysine 27 (H3K27)–specific isozyme overexpressed in a variety of human cancers, thwarts HCC tumorigenicity in a T cell–dependent manner. The tumor-suppressive effect of selective HDAC8 inhibition was abrogated by CD8+ T cell depletion or regulatory T cell adoptive transfer. Chromatin profiling of human HDAC8-expressing HCCs revealed genome-wide H3K27 deacetylation in 1251 silenced enhancer-target gene pairs that are enriched in metabolic and immune regulators. Mechanistically, down-regulation of HDAC8 increased global and enhancer acetylation of H3K27 to reactivate production of T cell–trafficking chemokines by HCC cells, thus relieving T cell exclusion in both immunodeficient and humanized mouse models. In an HCC preclinical model, selective HDAC8 inhibition increased tumor-infiltrating CD8+ T cells and potentiated eradication of established hepatomas by anti–PD-L1 therapy without evidence of toxicity. Mice treated with HDAC8 and PD-L1 coblockade were protected against subsequent tumor rechallenge as a result of the induction of memory T cells and remained tumor-free for greater than 15 months. Collectively, our study demonstrates that selective HDAC8 inhibition elicits effective and durable responses to ICB by co-opting adaptive immunity through enhancer reprogramming.

1 January 2022 in Cancer Letters
Verified
Journal Article
Closed access
FWFeng Wu
Feng Wu
LXLiangliang Xu
Liangliang Xu
YTYalin Tu
Yalin Tu
OCOtto Kw. Cheung
Otto Kw. Cheung
LSLemuel Lm. Szeto
Lemuel Lm. Szeto
Ka Fai ToKa Fai To
Ka Fai To

14 July 2025 in Cancer Research
Verified
Journal Article
Open access
JLJiahuan Lu
Jiahuan Lu
TCThomas Ting-Hei Chan
Thomas Ting-Hei Chan
YWYun Wang
Yun Wang
JWJingya Wang
Jingya Wang
ZXZhewen Xiong
Zhewen Xiong
JZJingying Zhou
Jingying Zhou
Turning immunologically “cold” tumors “hot” is required for effective immune checkpoint inhibitor (ICI) treatment in hepatocellular carcinoma (HCC). Here, we identified Fas-associated death domain (FADD) as a key molecule upregulated in HCC with dense tumor-infiltrating CD8+ T cells and better response to ICIs. CRISPR-mediated knockout of Fadd in murine HCC cells led to increased tumor weights in immunocompetent, but not immunodeficient, mice. FADD deficiency also led to decreased intratumoral infiltration of CD8+ T cells and lower production of IFN-γ and TNF-ɑ. Mechanistically, phosphorylated FADD translocated into the nucleus where it interacted with Sam68 to upregulate NF-κB-induced transcription of CCL5, thereby promoting CD8+ T cell recruitment. Treatment with anti-PD-1 triggered FADD phosphorylation in ICI-sensitive tumors, which was not observed in ICI-resistant tumors. FADD activation through genetic or pharmacologic approaches overcame ICI resistance in orthotopic and spontaneous HCC mouse models in vivo. Together, these findings provide insights into combinatory immunotherapy approaches for HCC patients.

13 December 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
CCClooney C. Y. Cheng
Clooney C. Y. Cheng
MCMing Fung Cheung
Ming Fung Cheung
ALAh Young Lee
Ah Young Lee
QWQiong Wu
Qiong Wu
SCSavio Ho-Chit Chow
Savio Ho-Chit Chow
DLDanny Leung
Danny Leung
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and has limited therapeutic options. Epigenetic dysregulation plays a crucial role in hepatocarcinogenesis; however, its impact on cis-regulatory elements (CREs) and retrotransposons remains underexplored. Here, we investigated the epigenetic changes underlying the aberrant CRE and retrotransposon activity in HCC. We show that focal DNA hypomethylation of these elements is associated with transcriptional reprogramming. Notably, we uncover a dual regulatory mechanism for GPC3, a key diagnostic biomarker and immunotherapeutic target in HCC. This requires the concomitant reactivation of a fetal liver super-enhancer (SE) and DNA hypomethylation of CpG islands. Furthermore, DNA methylation loss drives cryptic activation of retrotransposons, some of which exhibit prognostic potential. Intriguingly, we identify a HERVE-int-derived long non-coding RNA that shows higher expression in patients with more aggressive tumors, poorer disease outcomes, and is correlated with molecular signatures associated with improved response to immunotherapy. Collectively, our findings reveal widespread epigenomic dysregulation of CREs and retrotransposons in HCC, highlighting new potential therapeutic strategies and biomarkers.

1 April 2018 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
PCP. Chan
P. Chan
MAM. Au
M. Au
WYW. Yang
W. Yang
CYC. Yan
C. Yan
KCK. Chiu
K. Chiu
CWCHUNYI WEN
CHUNYI WEN

1 April 2016 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
WYW. Yang
W. Yang
PCP.B. Chan
P.B. Chan
CWCHUNYI WEN
CHUNYI WEN
CYC.-H. Yan
C.-H. Yan
KCK. Chiu
K. Chiu